Pharsight

Nurtec Odt generic

Nurtec Odt is a migraine treatment drug owned by Pfizer. It contains the active ingredient rimegepant sulfate. It was first approved for market use on 27 February, 2020, and is available in tablet form for oral use. It holds a total of 3 patents.

When will Nurtec Odt generic be available?

The generic version of Nurtec Odt is projected to be available after 25 March, 2039, when the last patent (US11083724) expires. However, subject to any successful Para IV filings, drug patent challenges can be initiated from 28 February, 2024.

Nurtec Odt uses

Nurtec Odt is primarily used for the acute treatment of migraine in adults, both with and without aura. Additionally, it can also be used in the preventive treatment of episodic migraine in adults. The main contributing factor to its effectiveness is the active ingredient, rimegepant sulfate.

Nurtec Odt patent expiration

Nurtec Odt holds a total of 3 active patents. The patent relevant to the generic release date is US11083724 titled 'Rimegepant for CGRP related disorders', which is set to expire on 25 March, 2039. Below are the details of the patent:

Nurtec Odt dosage

Want to ask something?